Adult T-cell leukemia/lymphoma and HTLV-1

Current Hematologic Malignancy Reports

Volumn 2, Issue 4, 2007, Pages 257-264

  Mahieux, Renaud ^b   Gessain, Antoine ^a  

^a INSTITUT PASTEUR   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; ALEMTUZUMAB; ALPHA INTERFERON; ARSENIC TRIOXIDE; BORTEZOMIB; CARBOPLATIN; CD4 ANTIGEN; CYCLOPHOSPHAMIDE; DACLIZUMAB; DEHYDROXYMETHYLEPOXYQUINOMICIN; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; I KAPPA B; METHOTREXATE; MITOXANTRONE; PREDNISONE; PROTEASOME INHIBITOR; RANIMUSTINE; VINCRISTINE; VINDESINE; ZIDOVUDINE;

ALLOGENIC BONE MARROW TRANSPLANTATION; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; CYTOLOGY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMOGENESIS; LYMPHOCYTE PROLIFERATION; NONHUMAN; PATHOGENESIS; REVIEW; SEXUAL TRANSMISSION; SPASTIC PARAPLEGIA; SPINAL CORD DISEASE; STEM CELL TRANSPLANTATION; SURVIVAL RATE; T CELL LEUKEMIA; T CELL LYMPHOMA; VIRUS INFECTION; VIRUS TRANSMISSION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; CD4-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; ENDEMIC DISEASES; FEMALE; GENE PRODUCTS, TAX; GENES, PX; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; IMMUNOGLOBULIN G; IMMUNOPHENOTYPING; IMMUNOTHERAPY; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; INTERFERON-ALPHA; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MALE; OXIDES; PARAPARESIS, TROPICAL SPASTIC; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; ZIDOVUDINE;

EID: 38349019596     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-007-0035-x     Document Type: Review

References (63)

1. Poiesz BJ, Ruscetti FW, Gazdar AF, et al.: Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 1980, 77:7415-7419.
2. Takatsuki T: Adult T-cell leukemia in Japan. In Topics in Hematology. Edited by Seno S, Takaku F, Irino S. Amsterdam: Excerpta Medica; 1977:73-77.
3. Yoshida M, Miyoshi I, Hinuma Y: Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci U S A 1982, 79:2031-2035.
4. Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL: Global epidemiology of HTLV-1 infection and associated diseases. Oncogene 2005, 24:6058-6068.
5. Gessain A: Epidemiology of HTLV-1. In Human T-Cell Lymphotropic Virus Type 1. Edited by Holsberg P, Hatler D. Chichester, England: John Wiley & Sons; 1996:34-63.
6. Ureta-Vidal A, Angelin-Duclos C, Tortevoye P, et al.: Mother-to-child transmission of human T-cell-leukemia/lymphoma virus type I: implication of high antiviral antibody titer and high proviral load in carrier mothers. Int J Cancer 1999, 82:832-836.
7. Roucoux DF, Wang B, Smith D, et al.: A prospective study of sexual transmission of human T lymphotropic virus (HTLV)-I and HTLV-II. J Infect Dis 2005, 191:1490-1497.
8. Manns A, Murphy EL, Wilks R, et al.: Detection of early human T-cell lymphotropic virus type I antibody patterns during seroconversion among transfusion recipients. Blood 1991, 77:896-905.
9. Wattel E, Vartanian JP, Pannetier C, Wain-Hobson S: Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy. J Virol 1995, 69:2863-2868.
10. Verdonck K, Gonzalez E, Van Dooren S, et al.: Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis 2007, 7:266-281.
11. Gerard Y, Lepere JF, Pradinaud R, et al.: Clustering and clinical diversity of adult T-cell leukemia/lymphoma associated with HTLV-I in a remote black population of French Guiana. Int J Cancer 1995, 60:773-776.
12. Hanchard B: Adult T-cell leukemia/lymphoma in Jamaica: 1986-1995. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 13:S20-S25.
13. Pombo De Oliveira MS, Loureiro P, Bittencourt A, et al.: Geographic diversity of adult T-cell leukemia/lymphoma in Brazil. The Brazilian ATLL Study Group. Int J Cancer 1999, 83:291-298.
14. The third nation-wide study on adult T-cell leukemia/lymphoma (ATL) in Japan: characteristic patterns of HLA antigen and HTLV-I infection in ATL patients and their relatives. The T- and B-cell Malignancy Study Group. Int J Cancer 1988, 41:505-512.
15. Murphy EL, Hanchard B, Figueroa JP, et al.: Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I. Int J Cancer 1989, 43:250-253.
16. Takatsuki K, Yamaguchi K, Matsuoka M: Adult T-cell leukemia. In Human T-Cell Lymphotropic Virus type 1. Edited by Holsberg P, Hatler D. Chichester, England: John Wiley & Sons; 1996:219-246.
17. Shimoyama M: Diagnostic criteria and classification of clinical subtypes of adult T- cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 1991, 79:428-437.
18. Shimoyama M: Treatment of patients with adult T-cell leukemia-lymphoma: an overview. In Advances in Adult T-cell Leukemia and HTLV-1 Research. Edited by Takatsuki K, Hinuma Y, Yoshida M. Tokyo: Japan Scientific Societies Press; 1992:43-46.
19. Yamaguchi K, Nishimura H, Kohrogi H, et al.: A proposal for smoldering adult T-cell leukemia: a clinicopathologic study of five cases. Blood 1983, 62:758-766.
20. Yamaguchi K, Yoshioka R, Kiyokawa T, et al.: Lymphoma type adult T-cell leukemia - a clinicopathologic study of HTLV related T-cell type malignant lymphoma. Hematol Oncol 1986, 4:59-65.
21. Levine PH, Cleghorn F, Manns A, et al.: Adult T-cell leukemia/lymphoma: a working point-score classification for epidemiological studies. Int J Cancer 1994, 59:491-493.
22. + T cells.
23. Yano H, Ishida T, Inagaki A, et al.: Regulatory T-cell function of adult T-cell leukemia/lymphoma cells. Int J Cancer 2007, 120:2052-2057.
24. Shimoyama M, Sakurai M, Kamada N: Chromosomal aberrations in adult T-cell leukemia-lymphoma: summary of a karyotype review committee report. In Advances in Adult T-cell Leukemia and HTLV-1 Research. Edited by Takatsuki K, Hinuma Y, Yoshida M. Tokyo: Scientific Societies Press; 1992:95-105.
25. Sakashita A, Hattori T, Miller CW, et al.: Mutations of the p53 gene in adult T-cell leukemia. Blood 1992, 79:477-480.
26. Yamada Y, Kamihira S: Inactivation of tumor suppressor genes and the progression of adult T-cell leukemia-lymphoma. Leuk Lymphoma 2005, 46:1553-1559.
27. Yoshida M, Seiki M, Yamaguchi K, Takatsuki K: Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci U S A 1984, 81:2534-2537.
28. Kamihira S, Sugahara K, Tsuruda K, et al.: Proviral status of HTLV-1 integrated into the host genomic DNA of adult T-cell leukemia cells. Clin Lab Haematol 2005, 27:235-241.
29. Leclercq I, Mortreux F, Morschhauser F, et al.: Semiquantitative analysis of residual disease in patients treated for adult T-cell leukaemia/lymphoma (ATLL). Br J Haematol 1999, 105:743-751.
30. Tannir N, Riggs S, Velasquez W, et al.: Hypercalcemia, unusual bone lesions, and human T-cell leukemia-lymphoma virus in adult T-cell lymphoma. Cancer 1985, 55:615-619.
31. White JD, Zaknoen SL, Kasten-Sportes C, et al.: Infectious complications and immunodeficiency in patients with human T- cell lymphotropic virus I-associated adult T-cell leukemia/lymphoma. Cancer 1995, 75:1598-1607.
32. Gabet AS, Mortreux F, Talarmin A, et al.: High circulating proviral load with oligoclonal expansion of HTLV-1 bearing T cells in HTLV-1 carriers with strongyloidiasis. Oncogene 2000, 19:4954-4960.
33. Matsuoka M, Jeang KT: Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 2007, 7:270-280. This paper discusses the role of the Tax oncoprotein in the cellular transformation induced by HTLV-1. It describes how Tax initiates transformation by creating a cellular environment favoring aneuploidy.
34. Afonso PV, Zamborlini A, Saib A, Mahieux R: Centrosome and retroviruses: the dangerous liaisons [review]. Retrovirology 2007, 4:27.
35. Hanon E, Hall S, Taylor GP, et al.: Abundant Tax protein expression in CD4+ T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes. Blood 2000, 95:1386-1392.
36. Hanon E, Stinchcombe JC, Saito M, et al.: Fratricide among CD8(+) T lymphocytes naturally infected with human T cell lymphotropic virus type I. Immunity 2000, 13:657-664.
37. Gaudray G, Gachon F, Basbous J, et al.: The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription. J Virol 2002, 76:12813-12822.
38. Satou Y, Yasunaga J, Yoshida M, Matsuoka M: HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc Natl Acad Sci U S A 2006, 103:720-725. This paper shows that HTLV-I basic leucine zipper factor (HBZ) is transcribed from 3′-LTR in all ATL cells. Suppression of HBZ gene transcription inhibits proliferation of ATLL cells. Analyses of T-cell lines transfected with mutated HBZ genes might indicate that the HBZ gene could possess two functions in two different molecular forms.
39. Mesnard JM, Barbeau B, Devaux C: HBZ, a new important player in the mystery of adult T-cell leukemia. Blood 2006, 108:3979-3982. This review summarizes the current knowledge (different isoforms, functions, etc.) on HBZ (HTLV-1 bZIP factor), a novel viral protein encoded by the complementary strand of the HTLV-1 RNA genome.
40. Arnold J, Yamamoto B, Li M, et al.: Enhancement of infectivity and persistence in vivo by HBZ, a natural antisense coded protein of HTLV-1. Blood 2006, 107:3976-3982. The authors investigated the contribution of HBZ to HTLV-1-mediated immortalization, using rabbits inoculated with cells expressing HTLV-1 HBZ mutant viruses. The findings indicate that HBZ is not required for in vitro cellular immortalization but enhances infectivity and persistence in inoculated rabbits.
41. Bazarbachi A, Ghez D, Lepelletier Y, et al.: New therapeutic approaches for adult T-cell leukaemia. Lancet Oncol 2004, 5:664-672. This review summarizes the current knowledge on ATLL therapies and discusses promising new drugs such as arsenic trioxide, proteasome inhibitors, retinoids, and angiogenesis inhibitors, as well as cellular immunotherapy.
42. Tsukasaki K, Utsunomiya A, Fukuda H, et al.: Clinical trials for the treatment of ATLL by the Japan Clinical Oncology Group (JCOG) [abstract]. AIDS Res Hum Retroviruses 2007, 23:592-593.
43. Hermine O, Panelatti G, Ramos J, et al.: A worldwide meta-analysis of the use of zidovudine and interferon alpha for the treatment of adult T-cell leukemia/lymphoma [abstract]. AIDS Res Hum Retroviruses 2007, 23:597-598.
44. Datta A, Bellon M, Sinha-Datta U, et al.: Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood 2006, 108:1021-1029. This paper describes for the first time how AZT works in HTLV-1-infected cells.
45. Ramos JC, Ruiz P Jr, Ratner L, et al.: IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma. Blood 2007, 109:3060-3068.
46. Jeang KT, Giam CZ, Majone F, Aboud M: Life, death, and Tax: role of HTLV-I oncoprotein in genetic instability and cellular transformation. J Biol Chem 2004, 279:31991-31994.
47. Mori N, Yamada Y, Ikeda S, et al.: Bay 11-7082 inhibits transcription factor NF-κB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. Blood 2002, 100:1828- 1834.
48. Nasr R, El-Sabban ME, Karam JA, et al.: Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma. Oncogene 2005, 24:419-430.
49. Watanabe M, Ohsugi T, Shoda M, et al.: Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-κB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Blood 2005, 106:2462-2471.
50. Ishitsuka K, Hanada S, Suzuki S, et al.: Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids. Br J Haematol 1998, 103:721-728.
51. Bazarbachi A, El-Sabban ME, Nasr R, et al.: Arsenic trioxide and interferon-α synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I- transformed cells. Blood 1999, 93:278-283.
52. El-Sabban ME, Nasr R, Dbaibo G, et al.: Arsenic-interferon-α- triggered apoptosis in HTLV-I transformed cells is associated with Tax down-regulation and reversal of NF-κB activation. Blood 2000, 96:2849-2855.
53. Mahieux R, Pise-Masison C, Gessain A, et al.: Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage. Blood 2001, 98:3762-3769.
54. Hermine O, Dombret H, Poupon J, et al.: Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol J 2004, 5:130-134.
55. Waldmann TA: Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol 2007, 27:1-18.
56. Moura IC, Lepelletier Y, Arnulf B, et al.: A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients. Blood 2004, 103:1838-1845.
57. Janik JE, Dunleavy KE, Pittaluga SE, et al.: A pilot trial of alemtuzumab (Campath-1H) and dose adjusted EPOCH (DA-EPOCH) in CD52-expressing aggressive T cell malignancies [abstract]. AIDS Res Hum Retroviruses 2007, 23:606.
58. Morris J, Sharma K, O'Mahony D, et al.: A phase II study of the efficacy and toxicity of alemtuzumab (Campath) for treatment of HTLV-1-associated ATL [abstract]. AIDS Res Hum Retroviruses 2007, 23:632-633.
59. Fukushima T, Miyazaki Y, Honda S, et al.: Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia 2005, 19:829-834. In 40 patients with acute and lymphoma types of ATLL, allogeneic hematopoietic stem cell transplantation (allo-HSCT) was effective for some patients with aggressive ATLL, and graft-versus-ATLL effect could be achieved without graft-versus-host disease.
60. Kannagi M, Harashima N, Kurihara K, et al.: Tumor immunity against adult T-cell leukemia. Cancer Sci 2005, 96:249-255.
61. Okamura J, Utsunomiya A, Tanosaki R, et al.: Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood 2005, 105:4143-4145. In 16 patients with ATLL who underwent allogeneic stem cell transplantation with reduced conditioning intensity (RIST) from HLA-matched sibling donors after a conditioning regimen, the human HTLV-1 proviral load became undetectable in eight patients, showing that RIST is a feasible treatment for ATLL.
62. Tanosaki R, Kim S, Fukuda T, et al.: Reduced intensity stem cell transplantation is relatively safe and effective in patients with ATLL [abstract]. AIDS Res Hum Retroviruses 2007, 23:592.
63. Mahieux R, Gessain A: HTLV-1 and associated adult T-cell leukemia/lymphoma [review]. Rev Clin Exp Hematol 2003, 7:336-361.